Skip to main content
Premium Trial:

Request an Annual Quote

TimeLogic Expands Product Line and Staff In Response to Bullish Accelerator Market


Despite an economic climate that has forced many organizations to limit their capital spending, Time Logic CEO Jim Lindelien said that the market for his company’s bioinformatics accelerators not only remains strong, but continues to expand.

“Accelerated bioinformatics is a growing market for us because of our R&D commitment, and a market we will remain committed to for the long haul,” said Lindelien, who said the company invested over 25 percent of last year’s gross revenues into new product development activities. According to Lindelien, this level of R&D commitment “significantly outpaces industry norms in computing.” IBM, for example, spent six percent of its gross 2000 revenue on R&D.

In addition, Lindelien said, despite the large R&D investment, TimeLogic closed last year with a profit, “as we have done for 19 of the past 20 years.”

The company plans to continue this level of R&D investment in 2001.

TimeLogic’s development efforts have paid off in the form of its latest product, the My DeCypher accelerated workstation to be released as part of a recently formed partnership with Compaq. The workstation, which will be sold through Infocom, TimeLogic’s distribution partner in Japan, is based on Compaq’s Deskpro Proliant platforms and is the company’s first product roll-out on a Compaq system.

Lindelien described the My DeCypher as an “introductory” accelerator platform that comes in at a far lower price point “for small business and academic groups who do not have the budget or technical resources to build and administer large clusters of machines.”

While a typical DeCypher installation can range between $150,000 and $300,000 and replace the equivalent of 300-1000 CPUs, the My DeCypher should run around $40,000 to $50,000 and replace a server farm of 50-100 CPUs, Lindelien said.

In addition to the Compaq partnership, TimeLogic also formed a non-exclusive technical and marketing alliance with Sun Microsystems last year. “Our revenue opportunities with Sun are limited only by TimeLogic’s ability to grow at a head-spinning pace,” said Lindelien.

And TimeLogic’s product line isn’t the only part of the company that’s expanding. The company recently doubled its floor space by moving its corporate offices from Incline Village, Nev., to Crystal Bay, Nev., and is currently hiring additional technical and management staff.

Lindelien reported that the company recently made its first sales into Thailand, Denmark, and New Zealand and expects to exceed its sales figures from last year.

— BT

Filed under

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.